Renal Function In Nigerian Patients With Heart Failure.

10.5580/2bd4 ◽  
2012 ◽  
Vol 9 (2) ◽  
Keyword(s):  
Heart Failure ◽  
Renal Function ◽  
Patients With Heart Failure

scholarly journals Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-analysis

2013 ◽  
Vol 35 (7) ◽  
pp. 455-469 ◽  
Author(s):  
K. Damman ◽  
M. A. E. Valente ◽  
A. A. Voors ◽  
C. M. O'Connor ◽  
D. J. van Veldhuisen ◽  
...  
Keyword(s):  
Heart Failure ◽  
Renal Function ◽  
Renal Impairment ◽  
Meta Analysis ◽  
Worsening Renal Function ◽  
Patients With Heart Failure

Plasma Galectin-3 in Patients with Heart Failure: Relationship to Clinical Status, Pathophysiology of Heart Failure, and Renal Function

2011 ◽  
Vol 17 (8) ◽  
pp. S30
Author(s):  
Deepa M. Gopal ◽  
Maya Kommineni ◽  
Nir Ayalon ◽  
Christian Koelbl ◽  
Rivka Ayalon ◽  
...  
Keyword(s):  
Heart Failure ◽  
Renal Function ◽  
Clinical Status ◽  
Patients With Heart Failure ◽  
Galectin 3

Effects of angiotensin receptor neprilysin inhibitor on renal function in patients with heart failure: a systematic review and meta-analysis

2021 ◽  
pp. postgradmedj-2021-140132
Author(s):  
Yuwu Shi ◽  
Yiwen Wang ◽  
Junhong Chen ◽  
Chi Lu ◽  
Haochen Xuan ◽  
...  
Keyword(s):  
Heart Failure ◽  
Renal Function ◽  
Ejection Fraction ◽  
Serum Potassium ◽  
Cochrane Library ◽  
Control Group ◽  
Angiotensin Receptor ◽  
Neprilysin Inhibitor ◽  
Patients With Heart Failure ◽  
Angiotensin Receptor Neprilysin Inhibitor

The angiotensin receptor neprilysin inhibitor (ARNI) has been recommended as a first-line treatment in patients with heart failure (HF). However, the effects of ARNI on renal function remain controversial.The PubMed, Embase, the Cochrane Library of Trials and Web of Science were searched in the period from inception to 31 January 2021. Randomised controlled trial, cohort studies and observational studies reporting at least one of renal function indicators were included.In patients with HF with reduced ejection fraction (HFrEF), ARNI did not lead to a significant decrease in estimated glomerular filtration rate (eGFR, p=0.87), and the risk of worsening renal function (WRF) dropped by 11% compared with control group. Though the level of serum creatinine (SCr) and serum potassium had a slight increase (p=0.01; p=0.02), in contrast to the baseline level, but without clinical significance. In patients with HF with preserved ejection fraction (HFpEF), the level of SCr and serum potassium did not have a significant change, and patients with HFpEF assigned to ARNI had a much lower rate of WRF (p=0.0007). In contrast to control group, both patients with HFrEF and HFpEF had a less decrease in eGFR and a lower rate of hyperkalaemia in ARNI group.ARNI did not lead to a significant decrease in eGFR in HFrEF. Compared with control group, ARNI could delay the progression of decrease in eGFR and result in less events of hyperkalaemia in patients with HF. Besides, patients with HFpEF had a lower rate in the events of WRF.

scholarly journals Renal function dynamics following co‐administration of sacubitril/valsartan and empagliflozin in patients with heart failure and type 2 diabetes

2020 ◽  
Vol 7 (6) ◽  
pp. 3792-3800 ◽  
Author(s):  
Rafael Espriella ◽  
Antoni Bayés‐Genís ◽  
Herminio Morillas ◽  
Rafael Bravo ◽  
Verónica Vidal ◽  
...  
Keyword(s):  
Heart Failure ◽  
Type 2 Diabetes ◽  
Renal Function ◽  
Patients With Heart Failure
Sign in / Sign up

Export Citation Format

Share Document